Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon, Inc. announced the granting of inducement equity awards to three new non-executive employees under its 2022 Employment Inducement Award Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). These awards consist of options to purchase 243,000 shares of common stock, with an exercise price of $5.21 per share, vesting over four years. This initiative aims to attract and retain talent for the biopharmaceutical company focused on neuroinflammatory diseases.
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Annexon, Inc. (Nasdaq: ANNX) announced inducement grants to three new non-executive employees under its 2022 Employment Inducement Award Plan, approved on May 11, 2026. These grants, totaling options to purchase 243,000 shares of common stock at an exercise price of $5.21, vest over four years subject to continued service. This initiative aligns with Nasdaq Listing Rule 5635(c)(4) and aims to attract and retain talent in the biopharmaceutical company focused on neuroinflammatory diseases.
Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?
This article analyzes Annexon's financial health and growth prospects. It examines the company's balance sheet, particularly its cash burn rate and cash runway, to assess its ability to fund future operations and development. The piece suggests that while Annexon's cash position appears strong for now, investors should monitor its financial resources closely.
Annexon (ANNX) insiders/affiliates report 8.7M-share stake (5.4%)
BVF entities and affiliates have reported a significant aggregate beneficial ownership of 8,698,173 shares in Annexon, Inc. (ANNX), representing approximately 5.4% of the company's outstanding shares. This disclosure, made via an amended Schedule 13G/A filing, details individual holdings for BVF (4,644,823 shares), BVF2 (3,399,850 shares), and Trading Fund OS (522,906 shares) as of March 31, 2026. The percentages are calculated based on 160,474,333 shares outstanding plus an additional 2,027,384 shares issued from pre-funded warrants.
Annexon, Inc. - common stock (NQ: ANNX)
This article provides a collection of headline news and analyst ratings related to Annexon, Inc. (Nasdaq:ANNX) common stock, compiled primarily from Benzinga. It includes details on Q3 2022 earnings, analyst upgrades/downgrades, and news regarding clinical trial data and stocks hitting 52-week lows. The content spans from May 2023 back to early 2022, offering a historical overview of significant company and market events.
Director William Carson Acquires Additional Shares of Annexon In
Director William Carson purchased 8,000 shares of Annexon Inc (ANNX) on May 11, 2026, bringing his total holdings to 78,405 shares. This recent acquisition is part of a broader trend where Carson has bought 52,805 shares over the past year without any sales. On the day of the transaction, Annexon Inc shares were trading at $5.78, with a market capitalization of $892.941 million.
Director adds Annexon (ANNX) shares in Rule 10b5-1 plan purchase
Annexon, Inc. director William H. Carson purchased 8,000 shares of common stock at $5.78 per share in an open-market transaction. This acquisition increases his direct holdings to 78,405 shares and was executed under a pre-arranged Rule 10b5-1 trading plan. The transaction, detailed in a Form 4 SEC filing, indicates a planned rather than discretionary purchase.
ANNX: Late-stage neuroinflammatory therapies show strong efficacy, with global filings and robust pipeline
Annexon, Inc. (ANNX) is advancing differentiated complement pathway therapies for neuroinflammatory diseases, highlighting strong efficacy and safety in late-stage programs for geographic atrophy and Guillain-Barré syndrome. The company is pursuing commercial and regulatory strategies in the U.S. and Europe, alongside further development in small molecule candidates. This information is based on an audio transcript from the Bank of America Global Healthcare Conference 2026.
Goldman Sachs initiates Annexon Biosciences stock at Neutral on GA trial uncertainty
Goldman Sachs initiated coverage on Annexon Biosciences (NASDAQ:ANNX) with a Neutral rating and a $7.00 price target, citing uncertainty around the Phase 3 trial data for its geographic atrophy (GA) treatment, vonaprument. The firm highlighted that the Phase 3 data for vonaprument, expected in Q4, is a binary event focused on vision preservation, but questioned the likelihood of success given a lack of statistical significance in Phase 2. Despite this, Annexon is also advancing other programs, and other analysts like Jefferies and H.C. Wainwright maintain Buy ratings with higher price targets, emphasizing the company's potential in the complement inhibitor space.
Analysts Offer Insights on Healthcare Companies: Amylyx Pharmaceuticals Inc (AMLX), Annexon Biosciences (ANNX) and AMN Healthcare Services (AMN)
Healthcare sector analysts have provided recent ratings for three companies. Amylyx Pharmaceuticals Inc (AMLX) received a "Strong Buy" consensus with a $24.57 average price target. Annexon Biosciences (ANNX) also has a "Strong Buy" consensus, with an average price target of $15.40, while AMN Healthcare Services (AMN) holds a "Moderate Buy" consensus, with an average price target of $23.50.
Annexon, Inc. Stock 12‑Month Price Target Raised to $14.38, Implies 160% Upside
The average 12-month price target for Annexon, Inc. (ANNX) stock has been raised from $14.12 to $14.38 by 8 analysts, suggesting a 160% potential upside based on the May 7 closing price. The consensus rating remains "Buy" from 10 analysts.
Annexon Inc expected to post a loss of 29 cents a share - Earnings Preview
Annexon Inc (ANNX) is expected to announce an earnings loss of 29 cents per share. This information comes from a Refinitiv earnings preview. The article is very short, offering this solitary financial projection.
TD Cowen Maintains Annexon(ANNX.US) With Buy Rating
TD Cowen has reiterated its Buy rating on Annexon (ANNX.US). This indicates continued confidence from the analyst firm in the company's prospects.
Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones
Annexon, Inc. reported its first quarter 2026 financial results, highlighting significant progress across its neuroinflammatory disease portfolio and reaffirming its financial runway into the second half of 2027. Key upcoming milestones include pivotal Phase 3 data for vonaprument in Geographic Atrophy expected in Q4 2026, a BLA submission for tanruprubart in Guillain-Barré Syndrome in 2026, and proof-of-concept data for ANX1502 for autoimmune conditions in 2026. The company maintains a strong balance sheet with approximately $225 million in cash, cash equivalents, and short-term investments as of March 31, 2026.
Annexon (NASDAQ: ANNX) trims Q1 2026 loss, targets key GA and GBS milestones
Annexon, Inc. (NASDAQ: ANNX) reported a narrowed net loss of $44.1 million for Q1 2026, down from $54.4 million a year ago, primarily due to decreased R&D expenses. The company highlighted significant progress in its neuroinflammatory pipeline, including anticipated topline Phase 3 data for vonaprument in geographic atrophy by Q4 2026 and a Biologics License Application submission for tanruprubart in Guillain-Barré syndrome within 2026. Annexon expects its $225 million in cash and investments to fund operations into the second half of 2027, underpinning these crucial milestones.
Annexon to Present at the Bank of America Securities Health Care Conference 2026
Annexon, Inc. announced that its President and CEO, Douglas Love, Esq., will present at the Bank of America Securities Health Care Conference 2026 on May 13, 2026. The biopharmaceutical company focuses on developing immunotherapies for neuroinflammatory diseases. A live webcast and replay of the presentation will be available on Annexon's investor relations website.
Annexon to Present at the Bank of America Securities Health Care Conference 2026
Annexon, Inc. announced that its President and CEO, Douglas Love, Esq., will present at the Bank of America Securities Health Care Conference 2026 on May 13, 2026, at 11:20 a.m. PT. A live webcast of the presentation will be available on the company's investor relations website, with a replay archived for 30 days. Annexon is a biopharmaceutical company focused on developing targeted immunotherapies for neuroinflammatory diseases.
Annexon to Present at Bank of America Securities Health Care Conference on May 6, 2026
Annexon, a clinical-stage biopharmaceutical company focused on autoimmune, neurodegenerative, and ophthalmic diseases, has announced it will present at the Bank of America Securities Health Care Conference on May 6, 2026, at 12:00 PM GMT. The specific topics for their presentation were not disclosed. The company develops therapies for classical complement-mediated diseases.
ANNX: Late-stage C1q inhibitors show strong efficacy in GBS and GA, with pivotal data due in 2026
Annexon (ANNX) is advancing late-stage C1q inhibitors for GBS and GA, utilizing a distinct C1q inhibition platform. Clinical data has demonstrated strong efficacy and safety for its leading therapies, vonaprument and tanruprubart. The company anticipates regulatory filings and pivotal data releases in 2026.
Annexon (NASDAQ: ANNX) proxy asks approval to boost share authorization and elect directors
Annexon, Inc. is seeking stockholder approval for four key proposals at its 2026 virtual annual meeting: electing two Class III directors, ratifying KPMG LLP as auditor for 2026, holding an advisory vote on executive pay, and significantly increasing authorized common stock from 300 million to 500 million shares. The company states the increase in authorized shares is crucial for future capital raising, strategic transactions, and equity incentives, noting a limited number of unissued shares remain. The board recommends voting "For" all proposals, emphasizing the need for flexibility in financing and compensation.
Annexon (ANNX): 7 Small Cap Stocks with the Highest Upside Potential
Annexon Inc. (ANNX) is highlighted as a small-cap stock with high upside potential, based on its 2025 year-end financial results and clinical advancements in its neuroinflammatory disease platform. The company has a strong cash balance and is progressing lead candidates like vonaprument for geographic atrophy (GA) and tanruprubart for Guillain-Barré Syndrome (GBS). While recognizing ANNX's potential, the article suggests that certain AI stocks might offer even greater upside with less risk.
Annexon (ANNX): 7 Small Cap Stocks with the Highest Upside Potential
Annexon Inc. (ANNX) is highlighted as a small-cap stock with high upside potential, having reported strong 2025 financial results with $238.3 million in cash and short-term investments, providing a financial runway into H2 2027. The company is advancing two late-stage programs: vonaprument for geographic atrophy (GA) with topline data expected in Q4 2026, and tanruprubart for Guillain-Barré Syndrome (GBS). The article also includes a promotional section for an AI stock report, suggesting AI companies might offer greater short-term returns.
Annexon, Inc. (NASDAQ:ANNX) Given Average Recommendation of "Moderate Buy" by Brokerages
Annexon, Inc. (NASDAQ:ANNX) has received a consensus "Moderate Buy" rating from seven brokerages, with an average 1-year target price of $17.00. Despite recent insider selling totaling $165,973, insiders still hold 12.67% of the stock. The company recently reported Q1 EPS of ($0.28), beating estimates, and aims to develop complement-targeted therapies for neurodegenerative and neuroimmune diseases.
Analysts Offer Insights on Healthcare Companies: Danaher (DHR), Annexon Biosciences (ANNX) and UnitedHealth (UNH)
This article provides an overview of analyst ratings for three healthcare companies: Danaher (DHR), Annexon Biosciences (ANNX), and UnitedHealth (UNH). Bank of America Securities maintained a Buy rating for Danaher with a $270.00 price target, while Needham maintained a Buy rating for Annexon Biosciences with an $11.00 price target. TD Cowen assigned a Hold rating to UnitedHealth with a $311.00 price target.
Does Annexon’s 2026 “Win Year” Milestone Roadmap Reshape The Bull Case For Annexon (ANNX)?
Annexon (ANNX) presented its "win year" roadmap for 2026, outlining key clinical and regulatory milestones including GBS regulatory filings, Phase III geographic atrophy readout, and ANX1502 proof-of-concept data, with a cash runway into H2 2027. This strategy reinforces the existing investment thesis, but its wide fair value estimates reflect the binary nature of trial outcomes and potential for dilution. Investors should consider multiple viewpoints and the company's financial health before making investment decisions.
Does Annexon’s 2026 “Win Year” Milestone Roadmap Reshape The Bull Case For Annexon (ANNX)?
Annexon presented its "win year" roadmap for 2026, highlighting expected GBS regulatory filings, a Phase III geographic atrophy readout, and ANX1502 proof-of-concept data, with a cash runway into mid-2027. This outlook reinforces the company's investment thesis, centered on translating its complement platform into approved products. While these milestones clarify near-term catalysts, the company still faces execution risk and potential dilution due to widening losses and ongoing equity issuance.
ANNX Price Today: Annexon, Inc. Stock Price, Quote & Chart | MEXC
This article provides current stock information for Annexon, Inc. (ANNX), including its live price, market data, and recent performance. It details how to buy ANNX on MEXC and offers a company overview, highlighting its focus on developing novel therapies for complement-mediated disorders. The piece also includes an extensive FAQ section covering various aspects of ANNX stock, such as price, performance trends, sector classification, market capitalization, and financial reporting.
Annexon (NASDAQ: ANNX) seeks vote to increase authorized shares to 500M
Annexon, Inc. (NASDAQ: ANNX) is soliciting stockholder approval to increase its authorized common stock from 300 million to 500 million shares at its 2026 Annual Meeting on June 11, 2026. This amendment would provide the Board with flexibility for future financing, equity incentives, and strategic relationships without requiring additional stockholder consent. The proxy statement also covers the election of two Class III directors, ratification of KPMG as auditor, and an advisory vote on executive compensation.
Annexon (NASDAQ:ANNX) Trading 8.5% Higher Following Insider Buying Activity
Annexon (NASDAQ:ANNX) shares rose 8.5% after Director William H. Carson purchased 8,000 shares for $6.20 each under a Rule 10b5-1 plan, increasing his total holdings to 70,405 shares. The clinical-stage biotech company, specializing in complement-targeted therapies, currently holds a "Moderate Buy" consensus rating with a $17.00 price target from analysts. Annexon's lead program, ANX005 for acute GBS, is in Phase 2 trials, and the company has a market cap of approximately $1.01 billion.
Carson buys $49k in Annexon (ANNX) stock By Investing.com
Annexon, Inc. Director William H. Carson purchased 8,000 shares of ANNX stock for $49,600 on April 10, 2026, under a pre-arranged trading plan. Despite a significant 280% return over the past year, the stock is currently trading below Carson's purchase price. Analyst firms Jefferies, H.C. Wainwright, and Cantor Fitzgerald have reiterated positive ratings for Annexon, citing M&A activity in the sector, distinctive clinical trial progress, and recent regulatory filings.
Carson buys $49k in Annexon (ANNX) stock By Investing.com
Director William H. Carson of Annexon, Inc. (NASDAQ:ANNX) recently purchased 8,000 shares of the company's common stock for $49,600, despite the stock trading below his purchase price after a significant 280% return over the past year. Analysts from Jefferies, H.C. Wainwright, and Cantor Fitzgerald have reiterated "Buy" or "Overweight" ratings on Annexon, citing positive developments like M&A activity in its sector and the company's first regulatory filing in the EU. InvestingPro analysis suggests the stock is currently undervalued.
Carson buys $49k in Annexon (ANNX) stock
Director William H. Carson of Annexon, Inc. (ANNX) recently purchased 8,000 shares of the company's stock for $49,600, despite the current trading price being below his purchase price. This transaction, executed under a pre-arranged trading plan, adds to his significant holdings. Analysts from Jefferies, H.C. Wainwright, and Cantor Fitzgerald have reiterated positive ratings for Annexon, citing promising developments in its drug pipeline and regulatory filings.
Annexon (NASDAQ: ANNX) director adds 8,000 shares in planned stock purchase
Annexon, Inc. (NASDAQ: ANNX) director William H. Carson purchased 8,000 shares of common stock at $6.20 per share on April 10, 2026, bringing his total direct holdings to 70,405 shares. This transaction was executed under a pre-scheduled Rule 10b5-1 trading plan adopted in December 2025. The purchase, valued at $49,600, signals insider confidence in the company.
Insider Buying: Annexon (NASDAQ:ANNX) Director Purchases 8,000 Shares of Stock
Annexon (NASDAQ:ANNX) Director William Carson recently purchased 8,000 shares of the company's stock at an average price of $6.20, totaling $49,600, under a pre-arranged Rule 10b5-1 trading plan. This transaction increased his holdings by 12.82% to 70,405 shares. Annexon, a clinical-stage biotechnology company, has a "Moderate Buy" consensus rating from analysts with an average price target of $17.00.
Carson buys $49k in Annexon (ANNX) stock
Annexon, Inc. Director William H. Carson recently purchased 8,000 shares of ANNX for $49,600, despite the stock currently trading below his purchase price. This insider buy follows significant analyst confidence from Jefferies, H.C. Wainwright, and Cantor Fitzgerald, who have maintained positive ratings and price targets due to the company's progress in clinical trials and regulatory filings for its drug candidates.
Annexon stock rises after director purchases shares
The article reports that Annexon's stock price increased following a director's purchase of shares. This insider transaction often signals confidence in the company's future performance to other investors.
Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference
Annexon, Inc. (Nasdaq: ANNX) announced that its president and chief executive officer, Douglas Love, Esq., will present at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026, at 11:45 a.m. ET. A webcast replay will be available on the company's website for 30 days. Annexon is a biopharmaceutical company focused on developing targeted immunotherapies for neuroinflammatory diseases by targeting C1q.
Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference
Annexon, Inc. (Nasdaq: ANNX) announced that its President and CEO, Douglas Love, Esq., will present at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026, at 11:45 a.m. ET. The presentation will be accessible via live webcast on Annexon's investor page, with a replay available for 30 days. Annexon is a biopharmaceutical company focused on developing targeted immunotherapies for neuroinflammatory diseases.
Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference
Annexon, Inc. announced that its president and CEO, Douglas Love, will present at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026, at 11:45 a.m. ET. The presentation will be accessible via a live webcast on Annexon's investor relations page, with a replay available for 30 days. Annexon is a biopharmaceutical company focused on developing targeted immunotherapies for neuroinflammatory diseases.
Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference
Annexon, Inc. (Nasdaq: ANNX) announced that its president and CEO, Douglas Love, Esq., will present at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026, at 11:45 a.m. ET. A live webcast of the presentation will be available on the Investors page of Annexon's website, with a replay archived for 30 days. The company is focused on advancing targeted immunotherapies for neuroinflammatory diseases.
Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference
Annexon, Inc. announced that its president and chief executive officer, Douglas Love, Esq., will present at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. A live webcast of the presentation will be available on the company's investor relations page, with a replay archived for 30 days. Annexon is a biopharmaceutical company focused on developing targeted immunotherapies for neuroinflammatory diseases.
Annexon (NASDAQ:ANNX) Shares Up 6.6% - What's Next?
Annexon (NASDAQ:ANNX) stock surged by 6.6% on Monday, trading at $5.8650, despite lower-than-average trading volume. Analysts hold a "Moderate Buy" consensus with an average price target of $17.00, driven by the company's lead asset, ANX005, which is in Phase 2 trials for neurological conditions. While institutions have significantly increased their holdings, company insiders have recently sold shares.
HC Wainwright Estimates Annexon FY2030 Earnings
HC Wainwright has projected Annexon's (NASDAQ:ANNX) FY2030 earnings per share (EPS) to be $0.43, a significant increase from the Street's consensus of ($0.96) per share. This revision follows Annexon's recent quarterly EPS of ($0.28), which beat analyst estimates by $0.04. The clinical-stage biotech company is currently trading around $5.50, with an average analyst target price of $17, indicating a "Moderate Buy" consensus.
Wall Street Analysts See a 165.52% Upside in Annexon (ANNX): Can the Stock Really Move This High?
Wall Street analysts project a 165.5% upside for Annexon (ANNX) with a mean price target of $14.71, based on seven short-term targets. Despite the potential for inflated price targets due to business incentives, Annexon's strong Zacks Rank #2 (Buy) and positive earnings estimate revisions suggest a legitimate upside potential. Investors are advised to view price targets with skepticism but consider the agreement among analysts and earnings forecast improvements as indicators.
H.C. Wainwright Maintains Annexon(ANNX.US) With Buy Rating, Maintains Target Price $14
H.C. Wainwright has reiterated its Buy rating for Annexon (ANNX.US) and maintained its target price at $14. This indicates a continued positive outlook from the analytical firm regarding Annexon's stock performance and potential.
Is Annexon (NASDAQ:ANNX) In A Good Position To Deliver On Growth Plans?
Annexon (NASDAQ:ANNX) has seen its share price soar by 183% in the last year, despite being an unprofitable company. The company had a cash runway of about 15 months as of December 2025, with analysts forecasting it to break even in approximately 4 years. While the increased cash burn of 58% over the last year is concerning, the company's solid cash runway and analyst forecasts for profitability suggest a manageable, though closely monitored, financial situation.
Multiple Insiders Sold Annexon Shares Presenting Weak Signs For Investors
The article highlights recent insider selling of Annexon (NASDAQ: ANSS) shares, which could be interpreted as a negative signal for investors. While some insider selling is routine, widespread selling across multiple insiders might suggest a lack of confidence in the company's future prospects. Investors should consider these transactions as part of their due diligence when evaluating the stock.
Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
Annexon, Inc. reported its fourth quarter and full year 2025 financial results, highlighting significant progress in its clinical pipeline with anticipated milestones for 2026. The company is advancing vonaprument for Geographic Atrophy (GA) with pivotal Phase 3 data expected in Q4 2026, tanruprubart for Guillain-Barré Syndrome (GBS) with a European MAA filed and U.S. BLA planned for 2026, and ANX1502 for autoimmune diseases. Annexon also reported a strong balance sheet with $238.3 million in cash and equivalents as of December 31, 2025, providing a cash runway into the second half of 2027.
Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
Annexon (NASDAQ: ANNX) reported its Q4 and full-year 2025 financial results, highlighting significant progress in its clinical pipeline. Key anticipated milestones include topline Phase 3 data for vonaprument in Geographic Atrophy in Q4 2026, a European MAA filing for tanruprubart in Guillain-Barré Syndrome with a planned U.S. BLA submission in 2026, and proof-of-concept data for ANX1502 in autoimmune disease in 2026. The company maintains a strong balance sheet with $238.3 million in cash as of December 31, 2025, providing an anticipated runway into the second half of 2027.
Annexon (NASDAQ:ANNX) Shares Gap Up - Should You Buy?
Annexon (NASDAQ:ANNX) shares gapped up by approximately 6.6% on Tuesday, opening at $5.64 after closing at $4.96. The clinical-stage biotech company, which focuses on complement-targeted therapies for neurodegenerative and neuroimmune diseases, holds a "Moderate Buy" consensus rating from analysts with an average price target of $17.00. Recent insider transactions show executives selling shares, while institutional investors have adjusted their positions, with the company reporting quarterly earnings per share of ($0.32), meeting analyst estimates.
